Treatise:Mechanism and Practice

Efficacy and safety of ciprofol dosing based on different body weight scalars combined with fentanyl for sedated gastroscopy in overweight and obese patients

  • Xiaomin HUANG ,
  • Zheng LIU ,
  • Xinjin CHI ,
  • Shuhua ZHAO ,
  • Xinggang MA
Expand
  • 1.Department of Anesthesiology,the Seventh Affiliated Hospital,Sun Yat?sen University,Shenzhen 518107,Guangdong,China
    2.Department of Anesthesiology,Shenzhen Children's Hospital (Affiliated Shenzhen Children's Hospital of Shantou University Medical College),Shenzhen 518000,Guangdong,China

Received date: 2026-02-07

  Online published: 2026-07-14

Abstract

Objective To evaluate the efficacy and safety of ciprofol dosing calculated using different body weight scalars—total body weight (TBW), adjusted body weight (ABW), and ideal body weight (IBW)—combined with fentanyl for procedural sedation during gastroscopy in overweight and obese patients. Methods A total of 294 overweight and obese patients (BMI 25 - 40 kg/m2) undergoing sedated gastroscopy at The Seventh Affiliated Hospital, Sun Yat-sen University, between March and September 2024 were enrolled. Participants were randomly assigned in a 1∶1∶1 ratio to one of three groups (n = 98 per group) using a random number table: TBW group, ABW group, or IBW group. Anesthesia was induced with fentanyl 50 μg plus ciprofol 0.4 mg/kg (calculated according to the assigned body weight scalar), followed by maintenance infusion of ciprofol at 1 mg/(kg·h) based on the same scalar. Primary outcomes included ciprofol rescue dose requirements and recovery time. Secondary outcomes encompassed sedation success rate, hemodynamic parameters (MAP, HR, SpO?) at predefined timepoints (T?: pre-induction; T?: scope insertion; T?: passage through piriform fossa; T?: pyloric examination; T?: procedure completion; T?: awakening in recovery room; T?: discharge from recovery), and incidence of adverse events. Results Compared with the TBW group, the IBW group required a significantly higher cumulative rescue dose of ciprofol (P 0.05) and achieved shorter recovery time (P 0.05). The ABW group also demonstrated shorter recovery time versus TBW (P 0.05), with no significant difference in rescue dose requirements (P 0.05). No significant differences were observed between the ABW and IBW groups regarding rescue dose or recovery time (both P 0.05). The incidence of adverse events—including respiratory depression, hypoxemia, hypotension, bradycardia, involuntary movement, cough, singultus, dizziness, nausea, and vomiting—and the sedation success rate did not differ significantly among the three groups (all P 0.05). Perioperative hemodynamic profiles remained stable and comparable across groups (all P 0.05). Conclusion For overweight and obese patients undergoing sedated gastroscopy, a ciprofol-fentanyl anesthesia regimen with ciprofol dosing calculated by adjusted body weight (ABW) provides optimal balance between anesthetic efficacy and recovery efficiency, while maintaining a favorable safety profile comparable to TBW- or IBW-based dosing. ABW-based dosing is therefore recommended as the preferred weight scalar in this population.

Cite this article

Xiaomin HUANG , Zheng LIU , Xinjin CHI , Shuhua ZHAO , Xinggang MA . Efficacy and safety of ciprofol dosing based on different body weight scalars combined with fentanyl for sedated gastroscopy in overweight and obese patients[J]. The Journal of Practical Medicine, 2026 , 42(13) : 2471 -2476 . DOI: 10.3969/j.issn.1006-5725.2026.13.024

References

[1] CHEN Y, ZHU X, DING S, et al. Minimally invasive treatment strategies for submucosal tumors of the upper gastrointestinal tract: Advances in innovative endoscopy-based therapies[J]. Eur J Surg Oncol, 2025, 51(5): 109626. doi: 10.1016/j.ejso. 2024.10.003 .
[2] ZHOU S, YU S, BI Y, et al. The safety and efficacy of remimazolam, ciprofol, and propofol anesthesia in endoscopy: A systematic review and network meta-analysis[J]. BMC Anesthesiol, 2025, 25(1): 230. doi: 10.1186/s12871-025-03108-w .
[3] ZHOU J, WANG L, ZHONG Z, et al. Pharmacological mechanism and clinical application of ciprofol[J]. Front Pharmacol, 2025, 15: 1572112. doi: 10.3389/fphar.2025.1572112 .
[4] YANG Y, PAN D, LI G, et al. Optimal dosing of ciprofol for gastrointestinal endoscopy: A systematic review and network meta-analysis[J]. BMC Gastroenterol, 2024, 24(1): 845. doi: 10.1186/s12876-024-04438-1 .
[5] YANG H, LAI P, QIN X, et al. Ciprofol Versus Propofol for Sedation in Gastrointestinal Endoscopy: A Systematic Review and Meta-Analysis in a Chinese Population[J]. Drug Des Devel Ther, 2024, 18: 2451-2465. doi: 10.2147/DDDT.S522678 .
[6] ORTEGAL G H, BARBOSA E C, FARIA P C, et al. Ciprofol versus propofol for adult sedation in gastrointestinal endoscopic procedures: A systematic review and meta-analysis[J]. Minerva Anestesiol, 2024, 90(11): 1013-1021. doi: 10.23736/S0375-9393.24.18203-X .
[7] ZHAO J, ZHANG Y, SU G, et al. The median effective dose of ciprofol combined with a low-dose sufentanil for gastroscopy in obese or nonobese patients: A dose-finding study using Dixon's up-and-down method[J]. Front Pharmacol, 2025, 16: 1521715. doi: 10.3389/fphar.2025.1521715 .
[8] CHEN J, LAI L, ZHAO S, et al. The effects of ciprofol and propofol on hypoxemia during gastrointestinal endoscopy in overweight and obese patients: A randomized controlled trial[J]. BMC Anesthesiol, 2025, 25(1). doi: 10.1186/s12871-025-03428-w .
[9] LI Y, YUAN M, ZHANG P,et al. Efficacy and Safety of Ciprofol for Anesthesia in Painless Colonoscopy with Varying Body Mass Indices Patients: A Prospective, Single-Center, Observational Study[J]. Drug Des Devel Ther, 2025, 19: 1-9. doi: 10.2147/DDDT.S496783 .
[10] HURWITZ E E, SIMON M, VINTA S R,et al.Adding Examples to the ASA-Physical Status Classification Improves Correct Assignment to Patients[J].Anesthesiology,2017,126(4):614-622. doi: 10.1097/ALN.0000000000001541 .
[11] American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists[J]. Anesthesiology, 2002, 96(4): 1004-1022. doi: 10.1097/00000542-200204000-00031 .
[12] CHUNG F, CHAN V W, ONG D. A post-anesthetic discharge scoring system for home readiness after ambulatory surgery[J]. J Clin Anesth, 1995, 7(6): 500-506. doi: 10.1016/0952-8180(95)00128-V .
[13] ZHANG J, LI H, XU M, et al. A randomized comparison of ciprofol versus propofol infusion for sedation in elective endoscopy: Hemodynamic and respiratory outcomes[J]. Sci Rep, 2025, 15(1): 1578. doi: 10.1038/s41598-025-14532-6 .
[14] WANG X, LI M, ZHANG Y, et al. Safety and efficacy of ciprofol for sedation in patients undergoing diagnostic and therapeutic procedures: A systematic review and meta-analysis of randomized controlled trials[J]. J Clin Anesth, 2024, 92: 111301. doi: 10.1016/j.jclinane.2023.111301 .
[15] LU M, LIU J, WU X, et al. Ciprofol: A novel alternative to propofol in clinical intravenous anesthesia [J]. Biomed Res Int, 2023, 2023: 7443226. doi: 10.1155/2023/7443226 .
[16] LI S, CHEN L, WANG J, et al. Population pharmacokinetics and dosing optimization of ciprofol in Chinese healthy subjects and patients: A pooled analysis[J]. Front Pharmacol, 2023, 14: 1164624. doi: 10.3389/fphar.2023.1164624 .
[17] XIE D, ZHANG Y, LI F, et al. Efficacy and safety of ciprofol for gastroscopy in patients with obesity: A randomised clinical controlled trial using different weight-based dosing scales[J]. BMC Anesthesiol, 2025, 25(1):112. doi:10.1186/s12871-025-02974-7 .
[18] SMITH R, JOHNSON P, LEE C. Pharmacokinetic alterations of sedative agents in obesity: Implications for individualized dosing strategies[J]. Clin Pharmacokinet, 2024, 63(4): 305-321. doi: 10.1007/s40262-023-01204-2 .
[19] TRAN T N, BOUCHAT J, PEETERS M, et al. Bleeding and perforation complications after follow-up colonoscopies in faecal immunochemical test-based colorectal cancer screening: Insights from a retrospective case-control study[J]. Gastrointest Disord, 2024, 6(1): 26-48. doi: 10.3390/gidisord6010003 .
[20] GERSTEIN N S, JENKINS T R, ARAS M A, et al. Long-term psychological consequences of accidental awareness during general anesthesia: A systematic review and meta-analysis of recent clinical cohorts[J]. Anesth Analg, 2024, 139(1): 112-124. doi: 10.1213/ANE.0000000000006930 .
[21] WANG J, LIU H, CHEN S, et al. Hemodynamic stability of ciprofol vs. propofol during gastrointestinal endoscopy induction: A real-world study of 1,200 obese patients[J]. Front Med (Lausanne), 2023, 10: 1245892. doi: 10.3389/fmed.2023.1245892 .
[22] LEE H Y, PATEL S, NGUYEN T, et al. Respiratory safety of ciprofol in high-BMI patients undergoing endoscopic procedures: A prospective cohort analysis[J]. J Gastroenterol Hepatol, 2025, 40(7): 1120–1128. doi: 10.1111/jgh.16100 .
[23] ZHANG Z, LIU X, HUANG P, et al. Comparison of ciprofol and propofol for sedation in obese patients undergoing gastrointestinal endoscopy: A multicenter, randomized, double-blind, non-inferiority trial[J]. Br J Anaesth, 2025, 134(2): 215-224. doi: 10.1016/j.bja.2024.10.015 .
[24] LIU Y, WANG J, ZHANG L, et al. Relationship between cumulative doses of ciprofol and recovery profiles in patients undergoing prolonged gastrointestinal procedures: A prospective observational study[J]. J Clin Pharm Ther, 2023, 48(3): 215-224. doi: 10.1111/jcpt.13845 .
[25] SMITH T, ROBERTS K, ANDERSON P, et al. The impact of weight-based dosing scalars on the recovery quality of sedated obese patients: A randomized comparison of TBW, IBW, and ABW[J]. Anesth Analg, 2024, 138(5): 1042-1053. doi: 10.1213/ANE.0000000000006821 .
Outlines

/